SPRUCE BIOSCIENCES, INC.
Spruce Biosciences, Inc. (OTCQB: SPRB) is a biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need. Founded in April 2016, the company is led by a management team experienced in developing and commercializing groundbreaking… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What SPRUCE BIOSCIENCES, INC. does
In the company’s own words
Spruce Biosciences, Inc. (OTCQB: SPRB) is a biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need. Founded in April 2016, the company is led by a management team experienced in developing and commercializing groundbreaking therapeutics. More information about the company is available at www.sprucebiosciences.com.
The company's primary focus is tralesinidase alfa enzyme replacement therapy (TA-ERT), a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase intended for treating Mucopolysaccharidosis Type IIIB (MPS IIIB), an ultra-rare, serious, and fatal genetic disease. TA-ERT has received Rare Pediatric Disease Designation, Fast Track Designation, Breakthrough Therapy Designation, and Orphan Drug Designation in the United States and European Union. The company plans to seek accelerated approval from the U.S. Food and Drug Administration based on existing clinical data, with a biologics license application submission anticipated in the fourth quarter of 2026.
Beyond TA-ERT, Spruce maintains a diverse portfolio of product candidates. The company is developing tildacerfont, a CRF1 receptor antagonist, and Cortibon, a companion diagnostic tool, for treating major depressive disorder through a strategic partnership with HMNC Holding GmbH. Additionally, Spruce licensed SPR202, an anti-CRH monoclonal antibody, from HBM Alpha Therapeutics for treating congenital adrenal hyperplasia and other indications.
Spruce's intellectual property portfolio includes 26 issued U.S. patents and numerous international patents and applications related to TA-ERT, tildacerfont, and SPR202, with exclusive licenses from Eli Lilly and Company, BioMarin Pharmaceutical Inc., and HBM Alpha Therapeutics. The company is building a specialized commercial organization to support TA-ERT commercialization in the United States, with plans to establish regional partnerships and third-party distributors for international markets. As a smaller reporting company, Spruce operates with a focus on serious diseases with clear underlying biology and significant unmet medical need.
Company details
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Headquarters
- SOUTH SAN FRANCISCO, CA
- Fiscal year end
- December
- CIK
- 1683553
- SIC
- 2834
Financial performance, year by year
Fiscal 2020–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns SPRUCE BIOSCIENCES, INC. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · SPRUCE BIOSCIENCES, INC.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do SPRUCE BIOSCIENCES, INC. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of SPRUCE BIOSCIENCES, INC.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in SPRUCE BIOSCIENCES, INC.'s last four quarterly filings that the numbers alone won't show?”